NeuroBo Pharmaceuticals, Inc
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch NRBO and buy or sell other stocks, ETFs, and their options commission-free!About NRBO
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases.
CEOHyung-Heon Kim
CEOHyung-Heon Kim
Employees9
Employees9
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2014
Founded2014
Employees9
Employees9
NRBO Key Statistics
Market cap18.01M
Market cap18.01M
Price-Earnings ratio-0.11
Price-Earnings ratio-0.11
Dividend yield—
Dividend yield—
Average volume119.59K
Average volume119.59K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$23.10
52 Week high$23.10
52 Week low$1.34
52 Week low$1.34
Stock Snapshot
The current NeuroBo Pharmaceuticals, Inc(NRBO) stock price is $8.18, with a market capitalization of 18.01M. The stock trades at a price-to-earnings (P/E) ratio of -0.11.
NeuroBo Pharmaceuticals, Inc(NRBO) stock opened on 2026-03-14 at —. The price climbed to — and dipped to —.
NeuroBo Pharmaceuticals, Inc(NRBO) shares are trading with a volume of 0, against a daily average of 119.59K.
During the past year, NeuroBo Pharmaceuticals, Inc(NRBO) stock moved between $1.34 at its lowest and $23.10 at its peak.
During the past year, NeuroBo Pharmaceuticals, Inc(NRBO) stock moved between $1.34 at its lowest and $23.10 at its peak.
People also own
Based on the portfolios of people who own NRBO. This list is generated using Robinhood data, and it’s not a recommendation.